AbbVie Inc (ABBV)vsPrecision BioSciences Inc (DTIL)
ABBV
AbbVie Inc
$294.64
-0.16%
HEALTHCARE · Cap: $520.47B
DTIL
Precision BioSciences Inc
$7.28
-3.77%
HEALTHCARE · Cap: $288.76M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 146461% more annual revenue ($66.01B vs $45.04M). ABBV leads profitability with a 15.7% profit margin vs -85.6%. DTIL trades at a lower P/E of 30.3x. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
DTIL
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.6%
Fair Value
$157.25
Current Price
$294.64
$137.39 premium
Margin of Safety
+56.6%
Fair Value
$9.38
Current Price
$7.28
$2.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 36.6%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 37272.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.
Bear Case : DTIL
The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a mature stock while DTIL is a hypergrowth play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.35 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 26/100), backed by strong 15.7% margins and 10.3% revenue growth. DTIL offers better value entry with a 56.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?